Computer-aided detection (CAD) and radiation therapy firm iCAD is highlighting positive research on the use of its Xoft Axxent electronic brachytherapy system for treating nonmelanoma skin cancer.
In a presentation on Tuesday at the American Society for Radiation Oncology (ASTRO) annual meeting, Dr. Ajay Bhatnagar of Cancer Treatment Services Arizona shared data showing that at three years post-treatment, patients who had high-dose-rate (HDR) electronic brachytherapy with the Xoft system had good cosmesis, low toxicity levels, and no recurrences, according to iCAD.
Clinical outcomes data were presented on 187 patients with 275 nonmelanoma skin cancer lesions treated by HDR electronic brachytherapy with surface applicators.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
